CNXUNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends October 31

Conexeu Sciences Inc.

Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026

$3.29+0.23 (+7.52%)

Close on Oct 19, 2026

Market cap: $88.74M
P/E (TTM): –
Dividend yield: –

Conexeu Sciences Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-10-31	FY 2024 2024-10-31
Cash & Equivalents	4.81	0.31
Cash & Short-Term Investments	4.81	0.31
Prepaid Expenses & Other	0.55	–
Total Current Assets	7.46	–
Property, Plant & Equipment	0.01	–
Gross Property, Plant & Equipment	0.02	–
Accumulated Depreciation	-0.01	–
Operating Lease Right-of-Use Assets	0	–
Intangible Assets	0.18	–
Total Assets	7.69	–
Accounts Payable	0.26	–
Current Portion of Leases	0	–
Total Current Liabilities	0.34	–
Long-Term Leases	0	–
Operating Lease Liabilities	0	–
Total Liabilities	0.34	–
Preferred Stock	0	–
Common Stock	0.02	–
Additional Paid-In Capital	12	–
Retained Earnings	-4.52	–
Shareholders' Equity	7.35	0.09
Total Equity	7.35	0.09
Total Liabilities & Equity	7.69	–
Shares Outstanding(shares)	19	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 5.31
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 154.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 15.17
Dividend yield: –